No Data
No Data
Shandong Sito Bio-technology Co., Ltd. (SZSE:300583) Stock Rockets 26% But Many Are Still Ignoring The Company
Shandong Sito Bio-technology (300583.SZ) will distribute CNY 4.5 dividends per 10 shares for the year 2023, with the registration date on July 29th.
Shandong Sito Bio-Technology (300583.SZ) announced that the company will implement annual equity distribution for 2023, distributing 1.5 yuan (tax included) for every 10 shares.
Shandong Sito Bio-technology Disposes 90.43% Stake in Losing Italian Unit for 1 Euro
Shandong Sito Bio-Technology (300583.SZ): intends to transfer 90.43% equity and debt exemption of Lisapharma Company.
On June 7th, Gelunhui reported that Shandong Sito Bio-Technology (300583.SZ) announced that its wholly-owned subsidiary, Yihua Stock (Hong Kong) Co., Ltd. ('Yihua Stock'), holds 90.43% equity interest in Laboratorio Italiano Biochimico Farmaceutico Lisapharma S.p.A. ('Lisapharma' or 'target company'). Yihua Stock intends to transfer the above-mentioned equity interest to Dong Trade Co., Ltd. ('Dong Trade' or 'investor'). The company comprehensively considered the target company.
Saito Biotech (300583.SZ): Jinsaifu Biotech is mainly engaged in standardized cultivation of Chinese herbal medicines such as saffron and carbon-based chaihu, not involving longevity medicine
Gelonghui, May 23 | Saito Biotech (300583.SZ) said on the investor interactive platform that Runxin Thermal Power mainly provides steam heat to the industrial park where the company is located. Rongjun New Materials plans to supply some accessories for the company, and production and operation have not yet started. Jinsaifu Biotech is a company participating in the company. It is mainly engaged in standardized cultivation of Chinese herbal medicines such as saffron and carbon-based chaihu. It does not involve longevity medicine, and the company does not participate in specific operations. All of the company's business layout and expansion revolves around the company's industrial upgrading strategy to achieve the integrated development of “intermediates - high-end respiratory APIs - preparations”.
Saito Biotech (300583.SZ): The company is not involved in cellular immunotherapy technology
Gelonghui, May 10 | Saito Biotech (300583.SZ) is a good vanguard of investors. The company's main products are produced using genetic engineering technology and synthetic biological methods. Compared with traditional chemical production methods, the technology currently used by the company has the advantage of “two high, two low and one stable”. The company is not currently involved in cellular immunotherapy technology. Silver Valley Pharmaceutical, which is in the process of being acquired, is carrying out the opening and promotion of the new drug phenylcycloquine ammonium bromide nasal spray according to the plan.
No Data